Eight institutional shareholders hold more than 5% of Fluidigm ahead of its Nasdaq flotation.
Fluidigm, a US-based provider of healthcare products, plans to raise $86.25m in its Nasdaq flotation.
The company uses nanotechnology to control valves and fluids at a small scale in the biotechnology industry.
Fluidigm made a $12.6m loss on $23.2m of revenues in the first nine months of the year compared to a $14.25m loss on $17.8m turnover in the same period last year.
Investment banks Deutsche Bank and Piper Jaffray are co-lead underwriters of the initial public offering (IPO).…
